Psychopharmacoepidemiology of mental retardation: 1966 to 1995

Journal of Child and Adolescent Psychopharmacology

Volumn 7, Issue 4, 1997, Pages 255-266

  Singh, Nirbhay N ^a   Ellis, Cynthia R ^a   Wechsler, Hollis ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIMEMAZINE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOPENTHIXOL; DIAZEPAM; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; NITRAZEPAM; PHENOBARBITAL; PHENYTOIN; PSYCHOTROPIC AGENT; THIORIDAZINE; VALPROIC ACID;

DEMOGRAPHY; DRUG USE; HISTORY; HUMAN; MENTAL DEFICIENCY; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PREVALENCE; PSYCHOPHARMACOLOGY; REVIEW; STATISTICAL ANALYSIS;

EID: 0031426914     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.1997.7.255     Document Type: Review

References (78)

1. Altmeyer BK, Locke BJ, Griffin JC, Ricketts RW, Williams DE, Mason M, Stark MT: Treatment strategies for self-injurious behavior in a large service-delivery network. Am J Ment Deficiency 91:333-340, 1987
2. Aman MG: Psychoactive drugs in mental retardation. In: Treatment Issues and Innovations in Mental Retardation. Edited by Matson JL, Andrasik F. New York, Plenum Press, 1983, pp 455-513
3. Aman MG, Field CJ, Bridgman GD: City-wide survey of drug patterns among non-institutionalized mentally retarded persons. Appl Res Mental Retardation 6:159-171, 1985
4. Aman MG, Richmond G, Steward AW, Bell JC, Kissle RC: The Aberrant Behavior Checklist: Factorial validity and the effect of demographic/medical variables in American and New Zealand facilities. Am J Ment Deficiency 91:570-578, 1987
5. Aman MG, Sarphare G, Burrow WH: Psychotropic drugs in group homes: Prevalence and relation to demographic/psychiatric variables. Am J Ment Retard 99:500-509, 1995
6. Aman MG, Singh NN: Patterns of drug use, methodological considerations, measurement techniques, and future trends. In: Psychopharmacology of the Development Disabilities. Edited by Aman MG, Singh NN. New York, Pergamon Press, 1988, pp 1-28
7. Aman MG, Singh NN, Fitzpatrick J: The relationship between nurse characteristics and perceptions of psychotropic medications in residential facilities for the retarded. J Autism Dev Disord 17:511-523, 1987
8. Aman MG, Singh NN, White AJ: Caregiver perceptions of psychotropic medication in residential facilities. Res Dev Disab 8:449-465, 1987
9. Bates WJ, Smeltzer DJ, Amoczky SM: Appropriate and inappropriate use of psychotherapeutic medications for institutionalized mentally retarded persons. Am J Ment Deficiency 90:636-370, 1986
10. Beghi E, Bollini P, Di Mascio R, Cerisola N, Merloni T, Manghi E: Effects of rationalizing drug treatment of patients with epilepsy and mental retardation. Dev Med Child Neurol 29:363-369, 1987
11. Bisconer SW, Zhang X, Sine LF: Impact of a psychotropic medication and physical restraint review process on adults with mental retardation, psychiatric diagnoses, and challenging behaviors. J Dev Physical Disabilities 7:123-135, 1995
12. Briggs R: Monitoring and evaluating psychotropic drug use for persons with mental retardation: A follow-up report. Am J Ment Retard 93:633-639, 1989
13. Buck JA, Sprague RL: Psychotropic medication of mentally retarded residents in community long-term care facilities. Am J Ment Retard 93:618-623, 1989
14. Burd L, Fisher W, Vesely BN, Williams M, Kerbeshian J, Leech C: Prevalence of psychoactive drug use among North Dakota group home residents. Am J Ment Retard 96:119-126, 1991
15. Chadsey-Rusch J, Sprague RL: Maladaptive behaviors associated with neuroleptic drug maintenance. Am J Ment Retard 93:607-617, 1989
16. Civil Rights of Institutionalized Persons Act, 42 U.S.C. §1997, 1981
17. Clarke DJ, Kelley S, Thinn K, Corbett JA: Psychotropic drugs and mental retardation: 1. Disabilities and the prescription of drugs for behavior and for epilepsy in three residential settings. J Ment Deficiency Res 34:385-395, 1990
18. Craig TJ, Behar R: Trends in the prescription of psychotropic drugs (1970-1977) in a state hospital. Compr Psychiatry 21:336-345, 1980
19. Cullinan D, Gadow KD, Epstein MH: Psychotropic drug treatment among learning disabled, educable mentally retarded, and seriously emotionally disturbed students. J Abnorm Child Psychol 15:469-477, 1987
20. DiMascio A: An examination of actual medication usage in retardation institutions: A study of 2000 cases. Presented at the American Association on Mental Deficiency Convention, Portland, May 1975
21. Dura JR, Aman MG, Mulick JA: Medication use in an ICF/MR for nonambulatory severely and profoundly mentally retarded children. J Multihandicapped Person 1:155-160, 1988
22. Ellenor GL, Frisk A: Pharmacist impact on drug use in an institution for the mentally retarded. Am J Hosp Pharmacol 34:604-608, 1977
23. Epstein MH, Singh NN, Luebke J, Stout CE: Psychopharmacological intervention: II. Teacher perceptions of psychotropic medication for students with learning disabilities. J Learning Disabil 24:477-483, 1991
24. Errickson E, Bock W, Young RC, Silverstein BJ: Psychotropic drug use in Title XIX (ICF/MR) facilities for the mentally retarded in Minnesota. In: The Use of Medications in Controlling the Behavior of the Mentally Retarded: Proceedings. Edited by Young R, Kroll J. Minneapolis, University of Minnesota, 1981, pp 82-88
25. Fielding LT, Murphy RJ, Reagan MW, Peterson TL: An assessment program to reduce drug use with the mentally retarded. Hosp Commun Psychiatry 31:771-773, 1980
26. Findholt NE, Emmett CG: Impact of interdisciplinary team review on psychotropic drug use with persons who have mental retardation. Ment Retard 28:41-46, 1990
27. Fischbacher E: Prescribing in a hospital for the mentally retarded. J Ment Deficiency Res 31:17-29, 1987
28. Fredericks DW, Hayes LJ: Effects of drug changes and physician prescribing practices on the behavior of persons with mental retardation. J Dev Physical Disabil 7:105-122, 1995
29. Gadow KD: Children on Medication. San Diego, College Hill Press, 1986
30. Gadow KD, Kalachnik J: Prevalence and pattern of drug treatment for behavior and seizure disorders of TMR students. Am J Ment Retard 85:588-595, 1981
31. Glaser BA, Morreau LE: Effects of interdisciplinary team review on the use of antipsychotic agents with severely and profoundly mentally retarded persons. Am J Ment Deficiency 90:371-379, 1986
32. Gowdey CW, Zarfas DE, Phipps S: Audit of psychoactive drug prescriptions in group homes. Ment Retard 25:331-334, 1987
33. Greiner T: Problems of methodology in research with drugs. Am J Ment Deficiency 64:346-352, 1958
34. Hancock RD, Weber SL, Kaza R, Her KS: Changes in psychotropic drug use in long-term residents of an ICF/MR facility. Am J Ment Retard 2:137-141, 1991
35. Harder SR, Kalachnik JE, Jensen MA, Feltz J: Psychotropic drug use with successful and unsuccessful community placed developmentally disabled groups. Res Dev Disab 8:191-202, 1987
36. Hansen P, Keogh BK: Medical characteristics of children with educational handicaps: Implications for the pediatrician. Clin Pediatr 10:726-730, 1971
37. Harper DC, Wadsworth JS: Behavioral problems and medication utilization. Ment Retard 31:97-103, 1993
38. Harper DC, Wadsworth JS, Michael AL: Psychotropic drug use in older developmentally disabled with behavioral difficulties. Res Dev Disabil 10:53-60, 1989
39. Harvey RJ, Cooray SE: Neuroleptic usage in a community mental health handicap unit. Psychiatr Bull 17:557-600, 1993
40. Hill BK, Balow EA, Bruininks RH: A national study of prescribed drugs in institutions and community residential facilities for mentally retarded people. Psychopharmacol Bull 21:279-284, 1985
41. Hogg J: The administration of psychotropic and anticonvulsant drugs to children with profound intellectual disability and multiple impairments. J Intellectual Disabil Res 36:473-488, 1992
42. Intagliata J, Rinck C: Psychoactive drug use in public and community residential facilities for mentally retarded persons. Psychopharmacol Bull 21:268-278, 1985
43. Jacobson JW: Problem behavior and psychiatric impairment within a developmentally disabled population: III. Psychotropic medication. Res Dev Disabil 9:23-38, 1988
44. Lepler S, Hodas A, Cotter-Mack A: Implementation of an interdisciplinary psychotropic drug review process for community-based facilities. Ment Retard 31:307-315, 1993
45. Linaker OM: Frequency of and determinants for psychotropic drug use in an institution for the mentally retarded. Br J Psychiatry 156:525-530, 1990
46. Lipman RS: The use of pharmacological agents in residential facilities for the retarded. Presented at the Annual Convention of the American Association on Mental Deficiency, Denver, 1967
47. Lipman RS: The use of pharmacological agents in residential facilities for the retarded. In: Psychiatric Approaches to Mental Retardation. Edited by Menslascino F. New York, Basic Books, 1970, pp 387-398
48. Martin JE, Agran M: Psychotropic and anticonvulsant drug use by mentally retarded adults across community residential and vocational placements. Appl Res Ment Retard 6:33-49, 1985
49. Morgan R, Gopalaswany AK: Psychotropic drugs: Another survey of prescribing patterns. Br J Psychiatry 144:298-302, 1984
50. Pary R: Psychoactive drugs used with adults and elderly adults who have mental retardation. Am J Ment Retard 98:121-127, 1993
51. Poindexter AR: Psychotropic drug patterns in a larger ICF/MR facility: A ten-year experience. Am J Ment Retard 93:624-626, 1989
52. Poindexter AR, Berglund JA, Kolstoe PD: Changes in antiepileptic drug prescribing patterns in large institutions: Preliminary results of a five-year experience. Am J Ment Retard 98:34-40, 1993
53. Radinsky AM: A descriptive study of psychotropic and antiepileptic medication use with mentally retarded persons in three residential environments. Pittsburgh, PA, University of Pittsburgh, 1984. Doctoral dissertation
54. Rinck C, Calkins CF: Patterns of psychotropic medication use among older persons with developmental disabilities. J Appl Gerontol 8:216-227, 1989
55. Sachdev PS: Psychoactive drug use in an institution for intellectually handicapped persons. Med J Aust 155:75-79, 1991
56. Searle GF, Berelowitz GJ, Wright EC: The use of drugs for physical conditions in adults with mental retardation. J Ment Deficiency Res 33:69-79, 1989
57. Sheppard LC, Ballinger BR, Fenton GW: Anticonvulsant medication in a mental handicap hospital: 1972-1982. Br J Psychiatry 150:513-517, 1987
58. Singh NN: Moving beyond institutional care for individuals with developmental disabilities. J Child Fam Stud 4:129-145, 1995
59. Singh NN, Aman MG: Ecobehavioral assessment of pharmacotherapy. In: Ecobehavioral Analysis in Developmental Disabilities. Edited by Schroeder SR. New York, Springer-Verlag, 1990, pp 182-200
60. Singh NN, Ellis CR, Axtell PK: Psychopharmacology and steady-state behavior. In: Antecedent Control: Innovative Approaches for the Behavioral Support. Edited by Luiselli JK, Camerom MJ. Baltimore, Paul H. Brookes Publishing Co., 1998
61. Singh NN, Ellis CR, Donatelli L, Williams DE, Ricketts RW, Goza AB, Perlman N, Everly DE, Best AM, Singh YN: Professionals' perceptions of psychotropic medication for individuals with mental retardation in residential facilities in Texas. J Intellect Disabil Res 40:1-7, 1996
62. Singh NN, Epstein MH, Luebke J, Singh YN: Psychopharmacological intervention: I. Teacher perceptions of psychotropic medication for students with serious emotional disturbance. J Special Education 24:283-295, 1990
63. Singh NN, Epstein MH, Stout CE, Luebke J, Ellis CR: Psychopharmacological intervention: III. A comparison of teacher perceptions of psychotropic medication for students with learning disabilities or serious emotional disturbance. J Dev Physical Disabil 6:101-113, 1994
64. Singh NN, Guernsey TF, Ellis CR: Drug therapy for persons with developmental disabilities: Legislation and litigation. Clinic Psychol Rev 12:665-679, 1992
65. Singh NN, Winton ASW: Behavioral pharmacology. In: Behavioral Medicine and Developmental Disabilities. Edited by Luiselli JK. New York, Springer-Verlag, 1989, pp 152-179
66. Singh NN, Winton ASW: Behavioral monitoring of pharmacological interventions for self-injury. Appl Res Ment Retard 5:161-170, 1984
67. Spencer DA: A survey of the medication in a hospital for the mentally handicapped. Br J Psychiatry 124:507-508, 1974
68. Sprague RL: Overview of psychopharmacology for the retarded in the United States. Presented at the International Association for the Scientific Study of Mental Deficiency, Washington, DC, 1976
69. Sprague RL: Overview of psychopharmacology for the retarded in the United States. In: Research to Practice in Mental Retardation: Biomedical Aspects (Vol 3). Edited by Mittler P. Baltimore, University Park Press, 1977, pp 199-202
70. Stone RK, Alvarez WF, Ellman G, Horn AC, White JF: Prevalence and prediction of psychotropic drug use in California Developmental Centers. Am J Ment Retard 93:627-632, 1989
71. Thinn K, Clarke DJ, Corbett JA: Psychotropic drugs and mental retardation: 2. A comparison of psychoactive drug use before and after discharge from hospital to community. J Ment Deficiency Res 34:397-407, 1990
72. Tu J: A survey of psychotropic medication in mental retardation facilities. J Clin Psychiatry 40:125-128, 1979
73. Tu J, Smith T: Factors associated with psychotropic medication in mental retardation facilities. Compr Psychiatry 20:289-295, 1979
74. Tu J, Smith T: The eastern Ontario survey: A study of drug-treated psychiatric problems in the mentally handicapped. Can J Psychiatry 28:270-276, 1983
75. White AJR: Changing patterns of psychoactive drug use with the mentally retarded. N Z Med J 96:686-688, 1983
76. Wressell SE, Tyrer SP, Berney TP: Reduction in antipsychotic drug dosage in mentally handicapped patients: A hospital study. Br J Psychiatry 157:101-106, 1990
77. Zaharia ES, Struxness L: Comparative survey of drug use in a community service system. Ment Retard 29:191-194, 1991
78. Zimmerman RL, Heistad GT: Correlates of psychotropic drug treatment at Cambridge State Hospital. In: The Use of Medications in Controlling the Behavior of the Mentally Retarded: Proceedings. Edited by Young R, Kroll J. Minneapolis, University of Minnesota, 1980, pp 123-132